The comprehensive positive data across PWS, HO, and BBS strengthens the MC4R agonist thesis and supports Phase 3 advancement in PWS, which could open a new multi-thousand-patient market. Traders should watch for the company's Phase 3 initiation timeline for PWS and any subsequent regulatory feedback. The stock may re-rate as the PWS opportunity is priced in; note the historical calibration data showing weak average T+20 performance on prior bullish reports for RYTM, but the strength and breadth of these data across multiple indications represent a materially larger catalyst than prior filings.
Price Chart
Executive Summary
On June 13 and June 15, 2026, Rhythm Pharmaceuticals released positive interim clinical data from its Phase 2 trial of setmelanotide in Prader-Willi syndrome (PWS) and multiple data presentations across acquired hypothalamic obesity (HO), Bardet-Biedl syndrome (BBS), and PWS at ENDO 2026. Six-month PWS data showed a -3.06% mean BMI reduction, preservation of lean mass, and clinically meaningful hyperphagia improvements, with 8 of 10 moderate-to-severe patients achieving a ≥7-point HQ-CT reduction. Additional data showed -18.9% mean BMI reduction at 2.5 years in HO with setmelanotide, encouraging 1-year oral bivamelagon data in HO, and real-world BBS outcomes. The company confirmed plans to advance into Phase 3 trials for PWS, reinforcing the MC4R agonism thesis and expanding the addressable market opportunity.
Key Facts
- Setmelanotide in PWS: -3.06% mean BMI reduction at Month 6 (N=17); 8/10 moderate-to-severe hyperphagia patients achieved ≥7-point HQ-CT improvement
- Setmelanotide in acquired HO: -18.9% mean BMI reduction sustained at 2.5 years (n=11)
- Oral bivamelagon in HO: mean BMI reductions of 6.7% to 16.6% across dosing cohorts at Week 52 (n=26)
- Real-world BBS data (n=286): 62% of adults achieved ≥10% body weight loss at 12 months; significant reduction in outpatient obesity-related visits
- BBS RESTORE study (n=22): 93% reported no nighttime hunger after 6 months; use of other anti-obesity medications decreased by 25%
- Company estimates U.S. PWS addressable prevalence at 8,500-12,750 patients, with similar numbers in Europe
- Safety profile consistent with known setmelanotide tolerability across all indications
Financial Impact
Positive clinical data across PWS and HO support pipeline expansion into Phase 3 for PWS, a new indication with estimated addressable prevalence of 8,500-12,750 patients each in U.S. and Europe, potentially doubling or more the total addressable market for setmelanotide beyond current approved indications. No financial figures provided in the filing.
Risk Factors
- Phase 3 PWS trial design, enrollment, and execution risks remain; setmelanotide is already approved for HO and BBS
- Safety signals (injection site reactions, skin pigmentation, nausea) are well-characterized but may affect compliance in long-term use
- Potential competitive landscape for MC4R agonists in PWS
- Historical calibration shows only 32-37% of prior score 6-7 filings on RYTM moved up at T+20, suggesting market may have already priced some expectations
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-043170 |
| Exhibit: ex991rytmprpwsatendo2026.htm | 0001628280-26-043170 |
| Exhibit: ex992pwsatendo2026.htm | 0001628280-26-043170 |
| Document: 0001628280-26-043170-index-headers.html | 0001628280-26-043170 |
| Document: 0001628280-26-043170-index.html | 0001628280-26-043170 |
| Document: 0001628280-26-043170.txt | 0001628280-26-043170 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 17d ago | 144 | $96.77 $99.27 | ▼ −2.58% | ▼ −0.47% | $93.68 (+3.19%) |
Aug 17, 2026 6w ago | Insider Cluster | $115.25 $113.35 | ▲ +1.65% | ▲ +1.45% | $93.68 (+18.72%) |
Aug 17, 2026 6w ago | Insider Cluster | $115.25 $113.35 | ▼ −1.65% | ▼ −1.45% | $93.68 (−18.72%) |
Aug 4, 2026 8w ago | 8-K | $105.78 $112.85 | ▲ +6.68% | ▲ +6.78% | $93.68 (−11.44%) |
Aug 4, 2026 8w ago | Press Release | $105.78 $112.85 | ▲ +6.68% | ▲ +6.78% | $93.68 (−11.44%) |
Jul 8, 2026 12w ago | Press Release | $115.48 $106.09 | ▼ −8.13% | ▼ −8.00% | $93.68 (−18.88%) |
Jun 22, 2026 14w ago | 144 | $106.19 $110.04 | ▲ +3.63% | ▲ +2.61% | $93.68 (−11.78%) |
Jun 15, 2026 15w ago | 8-K | $89.72 $106.19 | ▲ +18.36% | ▲ +20.59% | $93.68 (+4.41%) |
Jun 15, 2026 15w ago | Press Release | $89.72 $106.19 | ▲ +18.36% | ▲ +20.59% | $93.68 (+4.41%) |
Jun 13, 2026 15w ago | Press Release | $89.70 $101.39 | ▲ +13.03% | ▲ +14.42% | $93.68 (+4.44%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access